Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 29 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/1/1992


1.		Phase III Randomized Trial of Radiotherapy plus IUDR as a Radiosensitizer vs Radiotherapy Alone in Patients with Unresectable Sarcoma (Summary Last Modified 04/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				15 to 80				NCI				NCI-88-C-02 NCI-T88-0022N, T88-0022

Last Modified: 2/1/2001 First Published: 9/1/1998


2.		Phase II Study of High Dose Cytarabine, Mitoxantrone, and Amifostine Followed by Consolidation with Cytarabine and Idarubicin, and Maintenance with Isotretinoin and Interferon Alfa in Previously Untreated Patients with Standard Risk Acute Myelogenous Leukemia and Its Variants (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				70 and under				NCI, Pharmaceutical / Industry				RUSH-AML-9754 ALZA-RUSH-AML-9754, NCI-V98-1445, NCT00003405

Last Modified: 4/1/1988


3.		Phase II Radiosensitization and Dose Enhancement with Idoxuridine and Stereotactic Implantation Followed by External Radiotherapy for Anaplastic Astrocytoma/Glioblastoma Multiforme (Summary Last Modified 04/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				20 and over				NCI				OSU-85HO205 NCI-T85-0190D, T85-0190

Last Modified: 11/14/2007


4.		Phase II Study of Radiosensitization with IUdR Concurrent with Radiotherapy in Patients with Unfavorable Neoplasms

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				15 to 80				NCI				NCI-88-C-0003B NCI-T88-0020N, T88-0020

Last Modified: 1/1/1992


5.		Phase II Evaluation of IUdR Infusion and Radiotherapy in the Treatment of Head and Neck, Truncal, Retroperitoneal, and Extremity Soft Tissue Sarcomas (Summary Last Modified 01/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				CCUM-8802 NCI-T88-0121O, T88-0121

Last Modified: 5/1/1998


6.		Phase II Study of LIF (CF/IUDR/5-FU) in Patients with Advanced Colorectal Cancer (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				GUMC-19692 NCI-T92-0070D, T92-0070

Last Modified: 10/1/1992


7.		Phase II Study of LIF (CF/IUDR/5-FU) in Patients with Advanced Pancreatic Cancer (Summary Last Modified 10/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				GUMC-19992 NCI-T92-0060D, T92-0060

Last Modified: 11/1/1994


8.		Phase I Pilot Study of Intra-Arterial 125I/131I-IUDR in Hepatic Metastases from Colorectal Cancer (Summary Last Modified 11/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				over 18								MSKCC-94014 NCI-V94-0461

Last Modified: 1/1/2000


9.		Phase I Study of Accelerated Hyperfractionated Radiotherapy and IUDR for High-Grade Gliomas (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				WCCC-CO-9392 NCI-T93-0059C, T93-0059

Last Modified: 6/1/1997


10.		Phase I Randomized Study of Intravenous IUDR in Advanced Malignancies (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				CHNMC-IRB-94146 NCI-T94-0201D, T94-0201

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute